Oryzon Genomics - Multiple data readouts in 2019 within cash reach
Oryzon is ramping up its R&D programme and plans to conduct a total of four mid-stage clinical trials with lead assets ORY-1001 (a specific...
77 Views
Oryzon Genomics - New data support holistic effects of ORY-2001
Recently, Oryzon has published a flurry of fresh preclinical data backing its products ORY-2001 and ORY-3001. Latest data from ORY-2001 expanded...
38 Views
ORY-1001 rights back to Oryzon
Roche’s decision to discontinue the development of ORY-1001 and return the rights to Oryzon was major recent news. Roche cited portfolio...
73 Views
Roche returns rights on ORY-1001
As reported yesterday, Roche has decided to discontinue the development of ORY-1001 (a selective LSD1 inhibitor) and return the rights to Oryzon,...
33 Views
ORY-2001 and ORY-3001 next in focus
Oryzon’s Q117 financial results were broadly in line with our expectations. The company’s partner, Roche is now solely responsible for ORY-1001’s...
109 Views